- Iopofosine I 131 Follow-Up Data Show Strong Efficacy in Waldenström MacroglobulinemiaIopofosine I 131 produced strong responses in Waldenström macroglobulinemia, according to 12-month folllow-up data from CLOVER WaM requested by the FDA.onclive · 2mo ago↗ source
- Dr McGregor on Key End Points of the STRIKE Trial of Tivozanib Plus Pembrolizumab in RCCBradley McGregor, MD, discusses the end points that will be evaluated in the phase 3 STRIKE trial of adjuvant tivozanib plus pembrolizumab in high-risk RCC.onclive · 2mo ago↗ source
- Dr Kuykendall on the Evolving JAK Inhibitor and Transplant Considerations in MyelofibrosisAndrew Kuykendall, MD, explains considerations for JAK inhibitor sequencing and the use of transplant in myelofibrosis.